Ofatumumab

Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL)^[1][2][3]. IC50 & Target:CD20/MS4A1 In Vitro: Ofatumumab (10 μg/mL; 6 h) significantly induces cell lysis in a complement-dependent cytotoxicity (CDC) assay of mantle cell lymphoma (MCL) cell lines, with an effect superior to that of Rituximab (HY-P9913), and is still active against resistant cells with low CD20 expression or high complement inhibitory protein (CD55/CD59) expression^[1].
Ofatumumab (10 μg/mL; 24-72 h) has direct killing of B-cell lymphoma cell lines, with an inhibitory effect similar to that of Rituximab^[1]. In Vivo: Ofatumumab (10 mg/kg; intravenous injection; days 0, 3, 7, and 10; 4 times in total) significantly delays tumor growth and prolongs mouse survival in the SCID mouse Z-138 cell subcutaneous xenograft tumor model, and its effect is superior to Rituximab (HY-P9913) (10 mg/kg)^[1].